Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
Open Access
- 14 July 2022
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 140 (2) , 152-156
Abstract
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.Keywords
This publication has 14 references indexed in Scilit:
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancerNature Medicine, 2021
- Delayed production of neutralizing antibodies correlates with fatal COVID-19Nature Medicine, 2021
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 2021
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNature Communications, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptorNature, 2013